CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD.

Iris KleerekooperMegan K HerbertHinke B KuiperijDouglas Kazutoshi SatoKazuo FujiharaDagoberto CallegaroRomain MarignierAlbert SaizMakbule SenelHayrettin TumaniBrigit A De JongS Anand TripIchiro Nakashima Marcel M Verbeek Axel Petzold

Published in: Journal of neurology, neurosurgery, and psychiatry (2020)

Our data indicate astrocytic injury occurs in some patients with double-Ab-seronegative NMOSD, which hints at the possible existence of yet undiscovered astrocytic autoimmune targets. We hypothesise that elevated GS and GFAP levels could identify those double-Ab-seronegative patients suitable to undergo in-depth autoimmune screening for astrocytic antibodies.

Keyphrases

end stage renal disease
multiple sclerosis
chronic kidney disease
ejection fraction
newly diagnosed
oxidative stress
prognostic factors
electronic health record
drug induced
machine learning
big data
deep learning
data analysis